Incretins Update: A Holistic Approach to Patients With Type 2 Diabetes and Cardiometabolic Comorbidities

Medical Minute 2: Multisystemic Actions of GIP/GLP-1 Coagonists
Download All
In this series of concise Medical Minute videos and ClinicalThought™ commentaries, expert faculty review the actions and clinical applications of current and emerging incretin-based therapies for persons with type 2 diabetes.
Carol Hatch Wysham, MD

Endogenous Incretins

In this concise Medical Minute video, become familiar with incretins and review how currently available GLP-1 receptor agonists target multiple pathophysiologic defects in T2D.

Carol Hatch Wysham, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Registered Dietitians/Dietetic Technicians, Registered: maximum of 0.25 CPEU(s) Released: August 9, 2021 Expired: August 8, 2022

Learn about endogenous incretins, their downstream effects, and role in type 2 diabetes.

Carol Hatch Wysham, MD Released: August 9, 2021

A brief history of the discovery of incretins and how incretin-based therapies revolutionized modern diabetes care.

Carol Hatch Wysham, MD Released: August 13, 2021

Multisystem Actions of GIP/GLP-1 Coagonists

In this concise Medical Minute video, review the role of the gut in glucose homeostasis and gain expert insight on how GIP/GLP-1 coagonists may harness multisystemic activity to improve outcomes in persons with T2D.

Carol Hatch Wysham, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Registered Dietitians/Dietetic Technicians, Registered: maximum of 0.25 CPEU(s) Released: August 18, 2021 Expired: August 17, 2022

In this concise Medical Minute video, review the role of the gut in glucose homeostasis and gain expert insight on how GIP/GLP-1 coagonists may harness multisystemic activity to improve outcomes in persons with T2D.

Carol Hatch Wysham, MD Released: August 18, 2021

When managing patients with type 2 diabetes, we must understand the complex contribution of obesity and the importance of approaching weight loss for treatment.

Carol Hatch Wysham, MD Released: September 2, 2021

Clinical Trial Results of GIP/GLP-1 Coagonists

In this concise Medical Minute video, gain expert insights on the clinical trial data supporting the use of tirzepatide to improve outcomes in persons with T2D.

Carol Hatch Wysham, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Registered Dietitians/Dietetic Technicians, Registered: maximum of 0.25 CPEU(s) Released: September 2, 2021 Expired: September 1, 2022

Gain expert insights on the clinical trial data supporting the use of tirzepatide to improve outcomes in persons with T2D.

Carol Hatch Wysham, MD Released: September 2, 2021

The dual GIP/GLP-1 receptor agonist has demonstrated efficacy in lowering A1C and body weight in the phase III SURPASS trials. Here’s my take on how it may fit into the treatment toolbox for type 2 diabetes.

Carol Hatch Wysham, MD Released: September 21, 2021

Holistic Treatment for T2D with Metabolic Comorbidities

In this concise Medical Minute video, gain expert insights and guideline-based recommendations for clinical management of persons with T2D and metabolic comorbidities, including cardiovascular disease and obesity.

Carol Hatch Wysham, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Registered Dietitians/Dietetic Technicians, Registered: maximum of 0.5 CPEU(s) Released: September 30, 2021 Expired: September 29, 2022

Gain expert insights on developing individualized treatment for patients with T2D and cardiometabolic comorbidities.

Carol Hatch Wysham, MD Released: September 30, 2021

Despite the advent of powerful therapeutics for type 2 diabetes, most patients do not achieve treatment goals. Here’s my take on small practice changes that can improve the care of this chronic, progressive disease.

Carol Hatch Wysham, MD Released: October 7, 2021
Provided by Clinical Care Options

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Endocrine Society Logo
Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding visit www.lillygrantoffice.com

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue